Lanean...
ASSESSING THE IMPACT OF SAFETY MONITORING ON THE EFFICACY ANALYSIS IN LARGE PHASE III GROUP SEQUENTIAL TRIALS WITH NON-TRIVIAL SAFETY EVENT RATE
In Phase III clinical trials for life-threatening conditions, some serious but expected adverse events, such as early deaths or congestive heart failure, are often treated as the secondary or co-primary endpoint, and are closely monitored by the data and safety monitoring committee. A naïve group se...
Gorde:
| Argitaratua izan da: | J Biopharm Stat |
|---|---|
| Egile Nagusiak: | , , , |
| Formatua: | Artigo |
| Hizkuntza: | Inglês |
| Argitaratua: |
2015
|
| Gaiak: | |
| Sarrera elektronikoa: | https://ncbi.nlm.nih.gov/pmc/articles/PMC4661138/ https://ncbi.nlm.nih.gov/pubmed/26010228 https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1080/10543406.2015.1052473 |
| Etiketak: |
Etiketa erantsi
Etiketarik gabe, Izan zaitez lehena erregistro honi etiketa jartzen!
|